GuangYuYuan Chinese Herbal Medicine Stock Forum

The market's lack of excitement over the stock suggests potential for stronger growth trends. Despite recent sell-off, long-term shareholders have gained 6% annually over half a decade, indicating the sell-off could be an opportunity.

Despite the company's improved revenue, industry growth projection is significantly higher. Elevated P/S ratio and high stock price, based on business turnaround hopes, suggest potential overvaluation risk.

The company's uninspiring revenue growth rate, coupled with lack of profits, still saw a 20% annual increase in share price. A 4.6% total return for shareholders over the last year nearly aligns with the market's -4.8% return.